ARA-290: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 28 studies and official documents checked

In short

ARA-290 (cibinetide) is a lab-made, 11-amino-acid piece of erythropoietin (EPO), the hormone that makes red blood cells. It was designed to switch on tissue repair without raising red blood cells. It has more human testing than most peptides sold online: trials in 22, 38 and 64 people with nerve damage from sarcoidosis, 48 with type 2 diabetes, 9 with an eye condition and 36 healthy volunteers. Nerve-fiber counts in the cornea rose in two trials and some symptom scores improved, but pain intensity improved as much on placebo, the diabetes nerve result came from a subgroup picked after the fact, and every trial lasted 4 to 12 weeks. The company that makes it sponsored the 64-person trial, and its officers co-wrote others. We found no phase 3 trial. It isn’t FDA-approved, and the EU’s orphan designation for sarcoidosis isn’t an approval.

EvidenceCellAnimalHumansix small trials, 4 to 12 weeks; none beyond that

You’ll often read that ARA-290 regrows nerves, relieves nerve pain without side effects, calms autoimmune disease, stacks with BPC-157 and comes with a standard twice-a-week schedule. This page covers what it is, what each trial tested, what the nerve-fiber and pain results show, and where it stands legally, including a sports rule most pages leave out.

Names and forms you’ll see

The names on ARA-290 products
Name What it is Studied in people?
ARA-290, ARA 290, ARA290 The code name used in the trials. An 11-amino-acid peptide from the helix-B surface of EPO (Brines et al., 2015) Yes: six trials, below
Cibinetide The international drug name used by the FDA’s registry and the European Medicines Agency (FDA GSRS; EMA) The same trials
pHBSP Short for pyroglutamate helix B surface peptide, another name for the same peptide in some papers (Liu et al., 2025) The same trials
“Innate repair receptor agonist” The class name its developers use. The receptor itself is disputed (Cheung Tung Shing et al., 2018) Not a product
EPO, erythropoietin The full hormone ARA-290 was cut from; a different drug that raises red blood cells Not covered here
Vials and other products sold online Forms sold under the ARA-290 name No study of these products found

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA’s registry lists it as cibinetide.

ARA-290 CAS numbers
Form CAS number Registry record
ARA-290 (cibinetide) 1208243-50-8 FDA GSRS

What ARA-290 is

ARA-290 is 11 amino acids long and weighs about 1,257 daltons. It was modeled on one surface of EPO, called helix B, to switch on a tissue-protection signal without the red-blood-cell signal (Brines et al., 2015).

Its developers say the signal runs through an “innate repair receptor” made of the EPO receptor and a second receptor called beta-common. In rats it relieved nerve-injury pain, and it did nothing in mice without the beta-common receptor (Swartjes et al., 2011). A 2018 lab study found no direct link between the outer parts of the two receptors, with or without ARA-290 (Cheung Tung Shing et al., 2018).

In people it leaves the blood fast: after an injection under the skin, the peak was about 3 ng/ml and the terminal half-life about 20 minutes (Brines et al., 2015).

What has been studied

In people: ARA-290 given

Human trials of ARA-290
Study Who What was used What it found
Heij et al., 2012 22 people with sarcoidosis and nerve symptoms; double-blind 2 mg into a vein three times a week for 4 weeks, or placebo Symptom list score improved more than on placebo (about 11.5 vs 2.9 points, p < 0.05), and so did two quality-of-life scores. Pain intensity and fatigue improved as much on placebo. No safety concerns
Dahan et al., 2013 38 people with sarcoidosis and small-nerve-fiber loss; double-blind; one hospital 4 mg under the skin daily for 28 days, or placebo Corneal nerve fiber area rose 14.5% (p = 0.022 against its own baseline) and fell 5.3% on placebo, not significant. Skin-biopsy fiber counts didn’t change significantly. Symptom score fell 12.2 vs 3.8 points; pain intensity fell about 9% in both groups; 6-minute walk +18.7 m vs −15.1 m. At 9 months the pain-interference and walking gains were no longer significant, but the symptom-score gain still was
Brines et al., 2015 48 people with type 2 diabetes and painful neuropathy; double-blind; 24 per group 4 mg under the skin daily for 28 days, then 28 days without HbA1c fell 0.16 points against 0.01 on placebo, in people who started near 7%. One pain score (PainDetect) improved 3.3 vs 1.1 points (p = 0.037); another (NPSI) improved about 20% in both groups; the small-fiber symptom list didn’t change in either. Corneal nerve density rose only in a subgroup picked afterward
Culver et al., 2017 64 people with sarcoidosis nerve loss and pain; phase 2b; sponsored by the developer (NCT02039687) 1, 4 or 8 mg under the skin daily for 28 days, or placebo Corneal nerve fiber area rose significantly only at 4 mg (about 700 square micrometers above placebo, p = 0.012); 1 mg and 8 mg weren’t significant. Pain improved in all groups, placebo included
Lois et al., 2020 9 people with diabetic macular edema, 8 finished; no control group (NCT06626971) 4 mg under the skin daily for 12 weeks No improvement in vision, retinal thickness, retinal sensitivity or tear production. A quality-of-life score improved. No serious events or antibodies. The registry lists the trial as terminated
Cerit et al., 2015 36 healthy volunteers; double-blind (NCT02070783) A single 2 mg dose A week later the brain’s response to happy faces was lower and attention to positive pictures higher. No effect on mood; the authors say it doesn’t clearly point to an antidepressant effect

No trial lasted beyond 12 weeks, and we found no phase 3. The registry also lists a 24-person trial in prediabetes and type 2 diabetes (NCT01933529), status unknown; we found no report of it.

Who ran and paid for the trials

  • The developer. Araim Pharmaceuticals sponsored the 64-person trial (NCT02039687). Three of its officers, Brines, Dunne and Cerami, co-wrote the 2013 and 2015 papers, and the 2015 paper says they own stock or options in the company (Dahan et al., 2013; Brines et al., 2015).
  • Outside groups. The 2013 and 2015 trials were run by a Leiden team, and the volunteer study and the eye trial were run at Leiden and Belfast (Cerit et al., 2015; Lois et al., 2020).
  • No repeat. We found no repeat of the nerve-fiber result in a trial the company didn’t sponsor or help write.

EvidenceCellAnimalHumansmall trials of 4 to 12 weeks, two in sarcoidosis, one in diabetes

Outside the trials

  • Three uncontrolled cases, 2026. Three people with tooth-nerve injury were treated with a mix that included BPC-157, TB-500 and ARA-290, a steroid and a local anesthetic, and recovered. The authors say spontaneous recovery can’t be excluded and causality can’t be established (Froum et al., 2026).

In animals

  • Nerve-injury pain, 2011 and 2014. In rats and mice, injections starting a day after nerve injury relieved pain behavior for up to 15 weeks, and did nothing in mice without the beta-common receptor (Swartjes et al., 2011). In rats, doses of 3 to 60 micrograms per kilogram relieved it for up to 20 weeks (Swartjes et al., 2014).
  • Sciatic nerve crush, 2025. In rats, ARA-290 and EPO cut early inflammation in nerve-support cells and aided recovery (Liu et al., 2025).
  • Colitis, 2017. In mice with gut inflammation, cibinetide improved weight gain and survival (Nairz et al., 2017).
  • Alzheimer’s-type mice, 2022. Early treatment of young mice slowed amyloid build-up and improved memory (Al-Onaizi et al., 2022).

EvidenceCellAnimalHuman

In dishes: the receptor

  • 2018. In test-tube work, the outer parts of the EPO receptor and the beta-common receptor didn’t specifically bind each other, with or without EPO or ARA-290. The authors call the receptor model controversial and say there is no direct evidence for it (Cheung Tung Shing et al., 2018).

EvidenceCellAnimalHuman

Two retracted papers on this peptide

  • Mouse blood-sugar study, 2014. A study reporting that ARA-290 lowered the risk of diet-induced insulin resistance in mice was retracted in 2024. The publisher found repeated image patterns it called manipulation and fabrication, and the authors couldn’t supply original data; the authors disagree (Collino et al., 2014; retraction notice). The 2015 diabetes trial paper cites it as support for expecting an effect on blood sugar (Brines et al., 2015).
  • Kidney-injury study of pHBSP, 2012. Retracted in February 2026 after concerns about some blots. The publisher found that a number of bands chosen for publication didn’t appear representative, and the Editor-in-Chief no longer has confidence in the data. The notice says three authors disagree and the others haven’t responded; the developer’s Brines and Cerami are among the authors (Patel et al., 2012; retraction note).
  • Not cited for any result here. A retraction doesn’t show the peptide does nothing, but two of the early animal papers behind it can’t be relied on.

The usual claims, checked

Common ARA-290 claims vs the studies
Claim Verdict What the studies found
It regrows nerves Mixed Corneal nerve fiber area rose in two sarcoidosis trials, but at 4 mg only in the larger one (Dahan et al., 2013; Culver et al., 2017). Skin-biopsy fiber counts didn’t change significantly in the first, and in diabetes the rise came only in a subgroup picked afterward (Brines et al., 2015). Each lasted 28 days
It relieves nerve pain Mixed Pain intensity improved as much on placebo in two sarcoidosis trials, and pain improved in every group in the third (Heij et al., 2012; Dahan et al., 2013; Culver et al., 2017). In diabetes, one pain score improved more than on placebo and another didn’t (Brines et al., 2015)
It improves function and exercise capacity Mixed 6-minute walk distance rose 18.7 m against a 15.1 m fall on placebo (p = 0.049), and the gain was no longer significant at 9 months (Dahan et al., 2013). In diabetes the rise was 3.5% (p = 0.09) (Brines et al., 2015)
It improves blood sugar and cholesterol Mixed In one trial, HbA1c fell 0.16 points against 0.01 on placebo, in people who started near 7%; the authors call the change small (Brines et al., 2015). A 24-person trial in prediabetes has no report we could find (NCT01933529)
It helps eye disease such as macular edema Contradicted In 9 people with diabetic macular edema, vision and retinal thickness didn’t improve, and the trial had no control group (Lois et al., 2020)
It lifts mood or works as an antidepressant Contradicted In 36 healthy volunteers one dose changed how the brain responded to emotional pictures but not mood, and the authors say it doesn’t clearly point to an antidepressant effect (Cerit et al., 2015)
It works through an “innate repair receptor” Mixed The effect needed the beta-common receptor in mice (Swartjes et al., 2011), but a 2018 lab study found no direct link between that receptor and the EPO receptor (Cheung Tung Shing et al., 2018)
It doesn’t raise red blood cells like EPO Supported In the 28-day trials, blood counts showed no clinically significant change (Dahan et al., 2013; Brines et al., 2015). The trials were short and didn’t test clotting
It has an excellent safety profile, with no side effects Mixed No antibodies and no significant blood-count changes were found, but one diabetes participant stopped after kidney function worsened and another died of a heart attack judged unrelated (Brines et al., 2015). The registry lists serious events in 3 treated people in the 64-person trial (NCT02039687). No trial ran beyond 12 weeks
It treats sciatica or surgical nerve injury Untested In rats with sciatic nerve crush it cut inflammation and aided recovery (Liu et al., 2025). In people, the only report is three uncontrolled tooth-nerve cases (Froum et al., 2026). No trial
It works better stacked with BPC-157 Untested No trial tested it with BPC-157. The only report that used both gave three people a mix of BPC-157, TB-500, ARA-290, a steroid and a local anesthetic, and the authors say causality can’t be established (Froum et al., 2026). See the BPC-157 page
It calms inflammation and autoimmune disease Untested In mice with colitis it improved weight gain and survival (Nairz et al., 2017). In people, the sarcoidosis trials measured nerve symptoms, not the disease, and we found no study of any autoimmune disease itself
The twice-a-week schedule online comes from the trials Contradicted The human trials gave it daily under the skin or three times a week into a vein, for 4 to 12 weeks, plus one single dose (Heij et al., 2012; Culver et al., 2017; Lois et al., 2020). We found no trial of a twice-a-week schedule
It is FDA-approved Contradicted No. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). The EU gave it an orphan designation for sarcoidosis in 2013, which isn’t an approval (EMA)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

What the studies used

Amounts used in the ARA-290 studies
Study What was tested Amount and schedule
Heij et al., 2012 Sarcoidosis nerve symptoms 2 mg into a vein, three times a week, for 4 weeks
Dahan et al., 2013 Sarcoidosis nerve loss 4 mg under the skin daily for 28 days, chosen after a blood-level study in 10 healthy volunteers
Brines et al., 2015 Type 2 diabetes with painful neuropathy 4 mg under the skin daily for 28 days. A 4 mg injection gave a peak of about 3 ng/ml and a half-life of about 20 minutes
Culver et al., 2017 Sarcoidosis nerve loss and pain 1, 4 and 8 mg under the skin daily for 28 days; only the 4 mg group was significant on the main measure
Lois et al., 2020 Diabetic macular edema 4 mg under the skin daily for 12 weeks
Cerit et al., 2015 Healthy volunteers A single 2 mg dose
Swartjes et al., 2011; Swartjes et al., 2014 Rats and mice with nerve injury 30 micrograms per kilogram, five times two days apart then weekly; and 3 to 60 micrograms per kilogram

A schedule in a trial isn’t a plan for anyone else. All the human trials gave it daily or three times a week for 4 to 12 weeks, except one single dose, and we found no study of any other schedule, of use beyond 12 weeks, or of an amount that would fit a person’s weight. These are amounts from studies, not advice for anyone to use.

Side effects and safety

  • Blood tests and antibodies. No clinically significant change in blood counts or chemistry was reported in two trials, and no antibodies to the peptide were found in the three trials that tested for them (Dahan et al., 2013; Brines et al., 2015; Lois et al., 2020).
  • Serious events. In the diabetes trial, one person stopped after kidney function worsened while on a water pill, and one died of a heart attack after a leg infection; the investigators judged the death unrelated (Brines et al., 2015). In the 64-person trial the registry lists serious events in 3 treated people (syncope, headache, chest tightness, shortness of breath and bowel inflammation at 1 mg; suicidal thoughts at 8 mg), and none at 4 mg or on placebo (NCT02039687).
  • Other events listed. Headache, diarrhea, fatigue, nausea and injection-site pain were the most listed events there; injection-site pain was listed more on placebo (4 people) than at any dose of ARA-290 (1 each) (NCT02039687).
  • How long. No trial ran beyond 12 weeks, and we found no study of use over months or years.
  • What is in the bottle. We found no independent analysis of ARA-290 vials or other products sold online.
  • Not studied. Pregnancy, children, kidney disease, other medicines, long-term use, and any schedule other than daily or three times a week.

Side effects people report from online products aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not an approved drug. The FDA’s approved-drug data return no product under cibinetide or ARA-290 (openFDA Drugs@FDA), and its page of bulk substances that may present significant safety risks doesn’t name it (FDA, 2026).
  • An EU orphan designation isn’t an approval. The European Commission granted orphan designation EU/3/13/1191 on 7 October 2013 for sarcoidosis (EMA).
  • US designations, by the company’s account. Announcements by the developer say the FDA granted Fast Track and orphan designations for sarcoidosis nerve pain and orphan designation for sarcoidosis (Fast Track announcement; orphan announcement). We didn’t find the FDA’s own listing, and neither is an approval.
  • Registered trials. ClinicalTrials.gov lists four phase 1 or 2 studies (NCT02039687; NCT01933529; NCT06626971; NCT02070783). We found no phase 3.
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Sport. The World Anti-Doping Agency’s 2026 list bans “innate repair receptor agonists” (S2.1.5), naming asialo EPO and carbamylated EPO, plus other substances with a similar structure or effect. It doesn’t name ARA-290, but its developers describe it as one, and a 2017 doping-lab paper calls it a prohibited peptide (WADA, 2026; Thomas et al., 2017).
  • “Research use only” vials and any use in people aren’t approved.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • Which condition. The trials were in sarcoidosis nerve damage and diabetic nerve pain. A page applying them to sciatica, surgery injury or “nerve repair” in general has gone past them.
  • The placebo group. Pain intensity improved on placebo too. A page that quotes a pain drop without the placebo number hasn’t shown a benefit.
  • Who wrote it. The developer sponsored one trial and co-wrote others. Ask whether a result was repeated by anyone else.
  • Picked afterward. The diabetes nerve result came from a subgroup chosen after the data were in.
  • The schedule. Compare any schedule you read with the ones the trials used: daily, or three times a week into a vein, for 4 to 12 weeks.
  • The sports rule. The class it belongs to is banned in sport.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether the corneal nerve-fiber gain means better nerve function, or lasts after the injections stop.
  • Whether anyone outside the company’s circle gets the same nerve results.
  • Whether it works for sciatica, surgery nerve injury, eye disease or autoimmune disease; the trials that tested eyes and mood were small or negative.
  • Whether it is safe beyond 12 weeks, in kidney disease, or at any schedule other than the ones tested.
  • What the receptor it acts on really is.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention ARA-290. We recheck every month. Last checked Nov 12, 2026.

Flagged studies that mention ARA-290

Retracted, withdrawn and flagged studies
Study What it was about Status
Collino et al., 2014 A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Retracted (2024) · notice
We cite it above, with this warning.
Patel et al., 2012 Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Retracted (2026) · notice
We cite it above, with this warning.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Swartjes et al., 2011 Anesthesiology No retraction or concern
Heij et al., 2012 Mol Med No retraction or concern
Dahan et al., 2013 Mol Med No retraction or concern
Swartjes et al., 2014 Mol Pain No retraction or concern
Brines et al., 2015 Mol Med No retraction or concern
Cerit et al., 2015 Eur Neuropsychopharmacol No retraction or concern
Culver et al., 2017 Invest Ophthalmol Vis Sci No retraction or concern
Thomas et al., 2017 Drug Test Anal No retraction or concern
Nairz et al., 2017 Sci Rep No retraction or concern
Cheung Tung Shing et al., 2018 Sci Rep No retraction or concern
Lois et al., 2020 J Clin Med No retraction or concern
Al-Onaizi et al., 2022 Brain Behav Immun No retraction or concern
Liu et al., 2025 Eur J Pharmacol No retraction or concern
Froum et al., 2026 Front Oral Health No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is ARA-290?

A lab-made peptide of 11 amino acids modeled on part of erythropoietin (EPO), designed to switch on tissue repair without raising red blood cells. Its drug name is cibinetide (Brines et al., 2015; FDA GSRS).

What is ARA-290 used for?

It is sold for nerve pain and repair. It was tested in people with nerve damage from sarcoidosis and type 2 diabetes, in a small eye trial and in healthy volunteers (Dahan et al., 2013; Brines et al., 2015).

Does ARA-290 work?

Partly, in small short trials. Corneal nerve fibers rose in two sarcoidosis trials and some symptom scores improved, but pain intensity improved as much on placebo and the main result isn’t repeated outside the company’s circle (Dahan et al., 2013; Culver et al., 2017).

Is ARA-290 safe?

Not shown beyond 12 weeks. No antibodies or blood-count changes were found, but a diabetes participant stopped after kidney function worsened, and the registry lists serious events in 3 treated people in the 64-person trial (Brines et al., 2015; NCT02039687).

What are the side effects of ARA-290?

The 64-person trial’s registry lists headache, diarrhea, fatigue, nausea and injection-site pain among events, and serious events in 3 treated people (NCT02039687). Side effects people report from online products come from users, not studies.

What is the ARA-290 dosage?

We don’t give dosing advice. The amounts in the trials were 2 mg into a vein three times a week, and 1, 4 or 8 mg under the skin daily, for 4 to 12 weeks (Heij et al., 2012; Culver et al., 2017). We found no trial of a twice-a-week schedule.

How long does ARA-290 take to work?

The trials measured at 4 weeks. In one, pain interference differed from placebo by the third week of daily injections and the symptom score by week 5. At 9 months the pain-interference and walking gains were no longer significant, but the symptom score still differed (Dahan et al., 2013).

Can ARA-290 regrow nerves?

Not shown. Corneal nerve fiber area rose in two sarcoidosis trials, at 4 mg in the larger one, but skin-biopsy counts didn’t change significantly and nobody showed better nerve function lasting beyond 28 days (Dahan et al., 2013; Culver et al., 2017).

Does ARA-290 raise red blood cells like EPO?

Not in the 28-day trials, where blood counts showed no clinically significant change. Those trials were short and didn’t test clotting (Dahan et al., 2013; Brines et al., 2015).

Can I take BPC-157 and ARA-290 together?

No trial tested the pair. The only report that used both treated three people with a mix of peptides, a steroid and a local anesthetic, and the authors say causality can’t be established (Froum et al., 2026). See the BPC-157 page.

Does ARA-290 help with diabetes?

One 48-person trial found HbA1c fell 0.16 points against 0.01 on placebo in people who started near 7%, and the authors call the change small. It isn’t repeated (Brines et al., 2015).

Does ARA-290 help sciatica or nerve injury?

Not shown in people. It helped rats with nerve injury, and the only human report is three uncontrolled tooth-nerve cases (Liu et al., 2025; Froum et al., 2026).

Is the innate repair receptor real?

It is disputed. The developers’ mouse work needed the beta-common receptor, but a 2018 lab study found no direct link between it and the EPO receptor (Swartjes et al., 2011; Cheung Tung Shing et al., 2018).

Who developed ARA-290, and who paid for the studies?

Araim Pharmaceuticals developed it and sponsored the 64-person trial; its officers co-wrote the 2013 and 2015 papers and own stock or options (NCT02039687; Brines et al., 2015).

Is ARA-290 banned in sports?

The World Anti-Doping Agency bans “innate repair receptor agonists” and similar substances; the 2026 list doesn’t name ARA-290, but a doping-lab paper calls it a prohibited peptide (WADA, 2026; Thomas et al., 2017).

Have any ARA-290 papers been retracted?

Yes, two early animal papers. A 2014 mouse blood-sugar study was retracted in 2024 for image problems, and a 2012 kidney-injury study of the same peptide was retracted in 2026 over blot concerns (retraction notice; retraction note). Neither is cited for any result here.

Is ARA-290 FDA approved or legal?

It isn’t an approved drug, and the EU’s orphan designation for sarcoidosis isn’t an approval (openFDA Drugs@FDA; EMA). Our guide to what to look for covers the routes people use.

Sources

  1. Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-6. PubMed 23168581
  2. Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19(1):334-45. PubMed 24136731
  3. Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20(1):658-66. PubMed 25387363
  4. Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. PubMed 28475703
  5. Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med. 2020;9(7):2225. PubMed 32674280
  6. Cerit H, et al. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol. 2015;25(12):2289-99. PubMed 26431906
  7. Froum S, et al. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026;7:1907109. PubMed 42876687
  8. Cheung Tung Shing KS, et al. EPO does not promote interaction between the erythropoietin and beta-common receptors. Sci Rep. 2018;8(1):12457. PubMed 30127368
  9. Swartjes M, et al. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology. 2011;115(5):1084-92. PubMed 21873879
  10. Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014;10:13. PubMed 24529189
  11. Liu G, et al. ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury. Eur J Pharmacol. 2025;997:177610. PubMed 40216181
  12. Nairz M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep. 2017;7(1):13012. PubMed 29026145
  13. Al-Onaizi MA, et al. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain Behav Immun. 2022;99:363-382. PubMed 34343617
  14. Thomas A, et al. Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports. Drug Test Anal. 2017;9(11-12):1799-1803. PubMed 28941172
  15. Collino M, et al. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol. 2014;171(24):5802-15 (retracted). PubMed 25164531. Retraction notice, Br J Pharmacol, 2024;181(8):1341: PubMed 38433016
  16. Patel NS, et al. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012;18(4):719-27 (retracted). PubMed 22415011. Retraction note, Mol Med, 2026;32:31: PubMed 41749083
  17. ClinicalTrials.gov. NCT02039687: Study of efficacy of ARA 290 on corneal nerve fiber density and neuropathic symptoms in sarcoidosis (Araim Pharmaceuticals), results posted. Record
  18. ClinicalTrials.gov. NCT01933529: Effects of ARA 290, an erythropoietin analogue, in prediabetes and type 2 diabetes (Karolinska), status unknown. Record
  19. ClinicalTrials.gov. NCT06626971: The use of ARA290 for the treatment of diabetic macular oedema (Belfast Health and Social Care Trust), terminated. Record
  20. ClinicalTrials.gov. NCT02070783: Cognitive and neural effects of ARA290 (Leiden University Medical Center). Record
  21. European Medicines Agency. EU/3/13/1191: orphan designation for treatment of sarcoidosis (cibinetide), October 7, 2013. EMA
  22. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for cibinetide, ARA 290, ARA-290 and pyroglutamyl, November 12, 2026: no match. openFDA
  23. Araim Pharmaceuticals. Announcements of FDA Fast Track and orphan drug designations for ARA 290. Fast Track Orphan
  24. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  25. World Anti-Doping Agency. 2026 Prohibited List, section S2.1.5. WADA document
  26. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  27. U.S. Food and Drug Administration. Global Substance Registration System: Cibinetide (UNII 9W5677JKDA). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.